Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer

Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer

It is aimed at investigating the changes of serum soluble programmed death-ligand 1 (sPD-L1) expression level in nonsmall cell lung cancer (NSCLC) before and after radiotherapy, the correlation of PD-L1, PD-1, and proteins of Akt (protein kinase B), mTOR, and HIF-1α, and the molecular mechanism of t...

Full description

Bibliographic Details
Main Authors:	Yanli Qu, Huan Wang, Hangyu Liu, Xiaohu Sun, Ji Li, Hong Yu
Format:	Article
Language:	English
Published:	Hindawi Limited 2021-01-01
Series:	BioMed Research International
Online Access:	http://dx.doi.org/10.1155/2021/8811751

Similar Items

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
by: Liu Shujun, et al.
Published: (2020-01-01)

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
by: Stephan Kruger, et al.
Published: (2017-05-01)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
by: Paul Buderath, et al.
Published: (2019-10-01)

High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer
by: Lars Hagmeyer, et al.
Published: (2021-03-01)

Analysis of the changes in PD-1/PD-L1 pathway function in nonsmall- cell lung cancer tissue before and after 125I seed implantation
by: Wen Zheng
Published: (2017-07-01)

Expression levels of sPD-L1 and VEGF in serum of patients with acute myeloid leukemia
by: Chun Zhang, et al.
Published: (2018-04-01)

Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials
by: Qiuling Zhao, et al.
Published: (2018-01-01)

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas
by: Shujun Liu, et al.
Published: (2020-01-01)

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
by: Minghui Liu, et al.
Published: (2021-03-01)

Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis
by: Yichao Geng, et al.
Published: (2021-02-01)

Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice
by: Tan Y, et al.
Published: (2021-05-01)

Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
by: Christian Bailly, et al.
Published: (2021-06-01)

Combinatorial assessment of ctDNA release and mutational burden predicts anti‐PD(L)1 therapy outcome in nonsmall‐cell lung cancer
by: Wenfeng Fang, et al.
Published: (2020-03-01)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
by: González-Cao M, et al.
Published: (2015-07-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review
by: Butuo Li, et al.
Published: (2021-03-01)

Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers
by: Yuehong Kong, et al.
Published: (2021-03-01)

Ultrasound-Mediated Co-Delivery of miR-34a and sPD-1 Complexed with Microbubbles for Synergistic Cancer Therapy
by: Qin Y, et al.
Published: (2020-04-01)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
by: Nicolas Villanueva, et al.
Published: (2018-09-01)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017-07-01)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
by: Jingjing Qu, et al.
Published: (2021-02-01)

Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment
by: Xiaohu Zheng, et al.
Published: (2021-05-01)

Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer
by: Zhansheng JIANG, et al.
Published: (2017-02-01)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
by: Jing W, et al.
Published: (2016-01-01)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
by: Si-Yang Liu, et al.
Published: (2017-07-01)

Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients
by: Rasoul Nasiri Kalmarzi, et al.
Published: (2017-04-01)

PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations
by: Xin Sun, et al.
Published: (2018-07-01)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
by: Yan Guo, et al.
Published: (2021-04-01)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
by: Liting Zhong, et al.
Published: (2021-05-01)

CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers
by: Feng Gao, et al.
Published: (2019-12-01)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
by: Ranjan Pathak, et al.
Published: (2020-12-01)

HIP1R Expression and Its Association with PD-1 Pathway Blockade Response in Refractory Advanced NonSmall Cell Lung Cancer: A Gene Set Enrichment Analysis
by: Young Wha Koh, et al.
Published: (2020-05-01)

Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors
by: Suliman Almahmoud, et al.
Published: (2019-09-01)

PD-1/PD-L1 immunotherapy blockade in solid tumors: role of PD-1/PD-L1 in cancer disease progression
by: Li, Vivian
Published: (2021)

Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors
by: Philipp Schubert, et al.
Published: (2020-10-01)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
by: Yunlong Zhao, et al.
Published: (2018-07-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
by: Rosemarie Tremblay-LeMay, et al.
Published: (2018-03-01)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
by: Bin Zhao, et al.
Published: (2020-07-01)

Cannot write session to /tmp/vufind_sessions/sess_43ij5qrfc3761iql7nojdo2bep